Treatment of type 2 diabetes mellitus in the older adult: A review

Endocrine Practice

Volumn 20, Issue 7, 2014, Pages 722-736

  Pratley, Richard E ^a   Heller, Simon R ^b   Miller, Mary Alice ^c  

^a FLORIDA HOSPITAL   (United States)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; INCRETIN; INSULIN; MEGLITINIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

COMORBIDITY; DIABETIC PATIENT; ELDERLY CARE; FUNCTIONAL STATUS; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; AGED; ANALYSIS; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; LIFESTYLE;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE;

EID: 84903536095     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP13192.RA     Document Type: Review

References (63)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet, 2011: Diagnosed and undiagnosed diabetes in the United States, all ages, 2010. Available at: http://www.cdc.gov/diabetes/pubs/estimates11.htm#1. Accessed November 1, 2013
2. The American Geriatric Society CliniCAl Practice GuiDeline: Diabetes mellitus in OlDer Persons. In collaboration with the CAlifornia HealthCAre Foundation/American Geriatrics Society GuiDelines. JAGS. 2003;51:S265-S280
3. American Diabetes Association (ADA). Standard of mediCAl CAre in diabetes - 2012. Diabetes CAre. 2012;35(Suppl 1):S11-S63
4. Szoke E, Shrayyef MZ, Messing S, et al. Effect of aging on glucose homeostasis. Accelerated Deterioration of betacell function in individuals with impaired glucose tolerance. Diabetes CAre. 2008;31:539-543
5. Neumiller JJ, Setter SM. Pharmacologic management of the olDer patient with type 2 diabetes mellitus. Am J Geriatr Pharmocother. 2009;7:324-342
6. Chau D, EDelman SV. CliniCAl management of diabetes in the elDerly. Clin Diabetes. 2001;19:172-175
7. Sinclair AJ, Task and Finish Group of Diabetes UK. Good cliniCAl practice guiDelines for CAre home resiDents with diabetes: an executive summary. Diabet Med. 2011; 28:772-777
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of compliCAtions in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:15:1577-1589
10. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular compliCAtions in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139
11. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcome in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-2572
12. Action to Control CArdiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559
13. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of CArdiovascular events: ImpliCAtions of the ACCORD, ADVANCE, and VA diabetes trials: A position statement of the American Diabetes Association and a scientific statement of the American College of CArdiology Foundation and the American Heart Association. Diabetes CAre. 2009;32:187-192
14. Meneilly GS. Pathophysiology of type 2 diabetes in the elDerly. Clin Geriatr Med. 1999;15:239-253
15. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, compliCAtions, and Death in olDer diabetic patients: the diabetes and aging study. Diabetes CAre. 2011;34:1329-1336
16. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglyCAemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55: 1577-1596
17. Australian Diabetes EduCAtors Association. GuiDelines for the Management and CAre of Diabetes in the ElDerly: TechniCAl Document. 2003. Available at: http://www.aDea. com.au/wp-content/uploads/2013/08/ElDerly-full-version.pdf Accessed November 1, 2013
18. EviDenced-based GuiDeline by the German Diabetes Association and the German Geriatric Society. Diagnosis, treatment and follow-up of diabetes mellitus in the elDerly, 2006. Available at: http://www.Deutsche-diabetes- gesellschaft.De/fileadmin/Redakteur/Leitlinien/Englische-Leitlinien/ GUIDELINE-DM-IN- ELDERLY-052004-190906.pdf Accessed November 1, 2013
19. VA/DoD CliniCAl Practice GuiDeline for the Management of Diabetes Mellitus, 2010. Available at: http://www.healthquality.va.gov/guiDelines/CD/ diabetes/DM2010- FUL-v4e.pdf Accessed November 1, 2013
20. Baruah MP, Kalra S, Unnikrishnan AG, et al. Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guiDelines. Indian J Endocrinol Metab. 2011;15:75-90
21. Sinclair AJ, Paolisso G, CAstro M, BourDel-Marchasson I, Gadsby R, Rodriguez Mañas L. European Diabetes Working Party for OlDer People 2011 cliniCAl guiDelines for type 2 diabetes mellitus. Executive summary. Diabetes Metab. 2011;37(Suppl 3):S27-S38
22. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in olDer adults: A consensus report. Diabetes CAre. 2012;35: 2650-2664
23. CAnadian Diabetes Association CliniCAl Practice GuiDelines Expert Committee, Meneilly GS, Knip A, Tessier D. Diabetes in the ElDerly: CliniCAl Practice GuiDelines. CAn J Diabetes. 2013;37(Suppl 1):S184-S190
24. Cho NH, Colagiuri S, Distller L, et al. Glucose Control Management and Targets. In: Managing OlDer People with Type 2 Diabetes: International Diabetes FeDeration Global GuiDeline, 2013. Available at: http://www.idf.org/sites/ Default/files/IDF%20GuiDeline%20for%20OlDer%20 People.pdf
25. Umpierre D, Ribeiro PA, Kramer CK, et al. PhysiCAl activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305:1790-1799
26. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P, CliniCAl GuiDelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a cliniCAl practice guiDeline From the American College of Physicians. Ann Intern Med. 2012;156:218-231
27. De Fronzo RA, Goodman AM. EffiCAcy of metformin in patients with non-insulin-DepenDent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-549
28. Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2:e001076
29. National Institute for Health and CliniCAl Excellence. Type 2 diabetes: the management of type 2 diabetes, NICE CliniCAl GuiDeline 87, 2010. Available at: http://www.nice.org.uk/guidance/CG87/chapter/1-Guidance#/#oralglucose- control-therapies-1-metformin-insulin-secretagogues-and-aCArbose. Accessed November 1, 2013
30. GLUCOPHAGE® (metformin hydrochloriDe tablets) [package insert] Bristol-Myers Squibb, Princeton, NJ, Approval 1994
31. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in olDer people. J Am Geriatr Soc. 1996;44:751-755
32. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin EpiDemiol. 1997;50: 735-741
33. Holstein A, Plaschke A, Egberts EH. Lower inciDence of severe hypoglyCAemia in patients with type 2 diabetes treated with glimepiriDe versus glibenclamiDe. Diabetes Metab Res Rev. 2001;17:467-473
34. Shorr RI, Ray WA, Daugherty JR, Griffin MR. InciDence of risk factors for serious hypoglycemia in olDer persons using insulin or sulfonylureas. Arch Intern Med. 1997;157:1681-1686
35. Holstein A, Hammer C, Hahn M, Kulamadayil NS, Kovacs P. Severe sulfonylurea-induced hypoglycemia: a problem of uncritiCAl functional prescription and Deficiencies of diabetes CAre in geriatric patients. Expert Opin Drug Saf. 2010;9:675-681
36. Papa G, FeDele V, Rizzo MR, et al. Safety of type 2 diabetes treatment with repagliniDe compared with glibenclamiDe in elDerly people: a randomized, open-label, two-period, cross-over trial. Diabetes CAre. 2006;29:1918-1920
37. Schwarz SL, Gerich JE, Marcellari A, Jean-Louis L, Purkayastha D, Baron MA. NategliniDe, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elDerly patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:652-660
38. Prandin (repagliniDe) tablets (0.5, 1 and 2 mg) [prescribing information]. Novo Nordisk, Inc.; Princeton, NJ: 2010
39. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation. 2003;108:2941-2948
40. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in olDer diabetes adults. J Clin Endocrinol Metab. 2006;91:3349-3354
41. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladDer CAncer through drug adverse event reporting. Diabetes CAre. 2011;34:1369-1371
42. Food and Drug Administration. MedWatch. The FDA Safety Information and Adverse Event Reporting Program Safety Information. Actos (pioglitazone): Ongoing Safety Review-Potential Increased Risk of BladDer CAncer [Internet], 2011. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMediCAlProducts/ucm226257.htm. Accessed November 1, 2013
43. Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL. AdVantages of alpha-glucosidase inhibition as monotherapy in elDerly type 2 diabetic patients. J Clin Endocrinol Metab. 1998;83:1515-1522
44. Josse RG, Chiasson JL, Ryan EA, et al. ACArbose in the treatment of elDerly patients with type 2 diabetes. Diabetes Res Clin Pract. 2003;59:37-42
45. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of aCArbose on insulin sensitivity in elDerly patients with diabetes. Diabetes CAre. 2000;23:1162-1167
46. Schwartz SL. Treatment of elDerly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother. 2010;8:405-418
47. Strain WD, Lukashevich V, Kothny W, Hoelinger MJ, Paldánius PM. Individualised treatment targets for elDerly patients with type 2 diabetes using vildagliptin add-on or long therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet. 2013; 382: 9890:409-416
48. Barnett AH, Huisman H, Jones R, Von Eynatten M, Patel S, Wooerle HJ. Linagliptin for patients aged 70 years or olDer with type 2 diabetes inaDequately controlled with common antidiabetes treatment: a randomised, double-blind, placebo controlled trial. Lancet. 2013;382: 1413-1423
49. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. CliniCAl experience with vildagliptin in the management of type 2 diabetes in a patient population ?75 years: a pooled analysis from a database of cliniCAl trials. Diabetes Obes Metab. 2011;13:55-64
50. Bode BW, Brett J, Falahati A, Pratley RE. Comparison of the effiCAcy and tolerability profile of liraglutiDe, a oncedaily human GLP-1 analog, in patients with type 2 diabetes ?65 and 51.Pawaskar M, Li Q, Reynolds MW.Metabolic outcomes of elDerly patient populations initiating exenatiDe BID versus insulin glargine in an ambulatory CAre setting.Curr Med Res Opin.2012;28:991-997
51. Pawaskar M, Li Q, Reynolds MW. Metabolic outcomes of elDerly patient populations initiating exenatiDe BID versus insulin glargine in an ambulatory CAre setting. Curr Med Res Opin. 2012;28:991-997
52. BYETTA® (exenatiDe) Injection [package insert] Amylin PharmaceutiCAls, Inc. San Diego, CA, Approval 2005
53. Bydureon® (exenatiDe) Injection [package insert] Amylin PharmaceutiCAls, Inc. San Diego, CA, Approval 2012
54. Victoza® (liraglutiDe [rDNA origin] injection) [package insert] Novo Nordisk, Inc., Princeton, NJ, Approval 2010
55. Onglyza® (saxagliptin) [Package Insert] Bristol-Myers Squibb, Princeton, NJ, Approval 2009
56. Januvia® (sitagliptin) tablets [Package Insert] Merck Sharp & Dohme, Whitehouse Station, NJ, Approval 2006
57. Kahn SE. Incretin therapy and islet pathology: a time for CAution. Diabetes. 2013;62:2178-2180
58. Egan AG, Blind E, DunDer K, De Graeff PA, Hummer BT, Bourcier T, Rosebraugh C. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N Engl J Med. 2014;370:794-797
59. Jover N, Traissac T, Pinganaud G, Moras JB, Rainfray M, BourDel-Marchasson I. Varying insulin use in olDer hospitalized patients with diabetes. J Nutr Health Aging. 2009;13:456-459
60. Budnitz, DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in olDer Americans. N Engl J Med. 2011;365:2002-2012
61. Mannucci E, Cremasco F, Romoli E, Rossi A. The use of insulin in elDerly patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2011;12:2865-2881
62. Zafon C, Creus C. A comparison on insulin regimen treatment of elDerly (70 years) and younger (70 years) type 2 diabetic patients in actual cliniCAl practice. Acta Diabetol .2013.50.33-37.
63. Wolffenbuttel BH, Klaff LJ, Bhushan R, Fahrbach L, Jiang H, Martin S. Initiating insulin therapy in elDerly patients with Type 2 diabetes: effiCAcy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. Diabet Med. 2009;26:1147-1155.